Literature DB >> 22350721

15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas.

Edwin O Onkendi1, Sarah Y Boostrom, Michael G Sarr, Michael B Farnell, David M Nagorney, John H Donohue, Michael L Kendrick, Kaye M Reid-Lombardo, William S Harmsen, Florencia G Que.   

Abstract

BACKGROUND: The aim of our study was to compare the outcomes of periampullary and extra-ampullary duodenal adenocarcinomas and segmental duodenal resection versus pancreatoduodenectomy and to evaluate prognostic factors.
METHODS: We performed a retrospective review of all adults treated for duodenal adenocarcinoma by operative resection at a large tertiary referral center from 1994 to 2009.
RESULTS: One hundred twenty-four patients had an operation for duodenal adenocarcinoma over a 15-year period (periampullary, n = 25, and extra-ampullary, n = 99). Ninety-nine patients (80%) underwent curative resection, including 24 (96%) with periampullary and 75 (76%) with extra-ampullary carcinomas. The average number of lymph nodes sampled was eight with segmental resection and 12 with pancreatoduodenectomy (p < 0.001). Five-year overall survivals were 37% for the entire cohort (n = 124), 37% in the extra-ampullary group, and 38% in the periampullary group. Tumor size (p = 0.20), positive nodes (p = 0.60), segmental resection versus pancreatoduodenectomy (p = 0.55), adjuvant therapy (p = 0.23), and R(1) versus R(0) resection (p = 0.21) were not associated with survival. In contrast, advanced T stage and pathologic grade were associated with poor survival.
CONCLUSION: Extra-ampullary and periampullary duodenal adenocarcinomas have similar survival after resection. For distal duodenal tumors, survival is improved by curative resection without being compromised by limited resection. The number of lymph nodes sampled was significantly less with segmental resection than pancreatoduodenectomy.

Entities:  

Mesh:

Year:  2012        PMID: 22350721     DOI: 10.1007/s11605-011-1808-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  The surgical treatment and outcome for primary duodenal adenocarcinoma.

Authors:  Shao-Liang Han; Jun Cheng; Hong-Zhong Zhou; Qi-Qiang Zeng; Sheng-Hong Lan
Journal:  J Gastrointest Cancer       Date:  2010-12

2.  Improving survival in adenocarcinoma of the duodenum.

Authors:  D R Joesting; R W Beart; J A van Heerden; L H Weiland
Journal:  Am J Surg       Date:  1981-02       Impact factor: 2.565

3.  Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum.

Authors:  D Stell; D Mayer; D Mirza; J Buckels
Journal:  Dig Surg       Date:  2005-01-19       Impact factor: 2.588

4.  Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?

Authors:  M G Hurtuk; S Devata; K M Brown; K Oshima; G V Aranha; J Pickleman; M Shoup
Journal:  Am J Surg       Date:  2007-03       Impact factor: 2.565

5.  Prognostic factors for primary duodenal adenocarcinoma.

Authors:  Hyung Geun Lee; Dong Do You; Kwang Yeol Paik; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 6.  Evaluation and management of periampullary tumors.

Authors:  William A Ross; Mike M Bismar
Journal:  Curr Gastroenterol Rep       Date:  2004-10

7.  Periampullary cancer treatment in U.S. Department of Veterans Affairs hospitals: 1987-1991.

Authors:  T P Wade; M A Coplin; K S Virgo; F E Johnson
Journal:  Surgery       Date:  1994-10       Impact factor: 3.982

8.  Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.

Authors:  Aaron Struck; Thomas Howard; Elena G Chiorean; Jeffrey M Clarke; Robert Riffenburgh; Higinia R Cardenes
Journal:  J Surg Oncol       Date:  2009-08-01       Impact factor: 3.454

9.  Improving resectability and survival in patients with primary duodenal carcinoma.

Authors:  R Delcore; J H Thomas; J Forster; A S Hermreck
Journal:  Am J Surg       Date:  1993-12       Impact factor: 2.565

Review 10.  Primary duodenal adenocarcinoma.

Authors:  Mario Solej; Silvia D'Amico; Gabriele Brondino; Marco Ferronato; Mario Nano
Journal:  Tumori       Date:  2008 Nov-Dec
View more
  26 in total

Review 1.  Successful percutaneous endobiliary radiofrequency ablation for unresectable malignant biliary obstruction: a case report and review of the literature.

Authors:  Eric J Mao; James B Watson; Gregory Soares; Fadlallah G Habr
Journal:  J Gastrointest Cancer       Date:  2014-12

2.  Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.

Authors:  Yue Xue; Alessandro Vanoli; Serdar Balci; Michelle M Reid; Burcu Saka; Pelin Bagci; Bahar Memis; Hyejeong Choi; Nobuyike Ohike; Takuma Tajiri; Takashi Muraki; Brian Quigley; Bassel F El-Rayes; Walid Shaib; David Kooby; Juan Sarmiento; Shishir K Maithel; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

3.  Postoperative morbidity is an additional prognostic factor after potentially curative pancreaticoduodenectomy for primary duodenal adenocarcinoma.

Authors:  Giuseppe Malleo; Alfredo Tonsi; Giovanni Marchegiani; Andrea Casarotto; Salvatore Paiella; Giovanni Butturini; Roberto Salvia; Claudio Bassi
Journal:  Langenbecks Arch Surg       Date:  2012-07-17       Impact factor: 3.445

4.  Side-to-side duodenojejunostomy after resection of third and fourth duodenal portions with pancreatic preservation.

Authors:  Gerardo Blanco-Fernández; Adela Rojas-Holguín; Noelia De-Armas-Conde; Isabel Gallarín-Salamanca; Diego López-Guerra; Isabel Jaén-Torrejimeno
Journal:  Updates Surg       Date:  2020-06-05

Review 5.  Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Pipit Burasakarn; Ryota Higuchi; Souya Nunobe; Shingo Kanaji; Hidetoshi Eguchi; Ken-Ichi Okada; Tsutomu Fujii; Yuichi Nagakawa; Kengo Kanetaka; Hiroharu Yamashita; Suguru Yamada; Shinji Kuroda; Toru Aoyama; Takahiro Akahori; Kenji Nakagawa; Masakazu Yamamoto; Hiroki Yamaue; Masayuki Sho; Yasuhiro Kodera
Journal:  Int J Clin Oncol       Date:  2021-01-01       Impact factor: 3.402

6.  Carbonic Anhydrases II and IX in Non-ampullary Duodenal Adenomas and Adenocarcinoma.

Authors:  Minna Nortunen; Seppo Parkkila; Juha Saarnio; Heikki Huhta; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2021-10-12       Impact factor: 2.479

7.  Effect of postoperative radiotherapy on survival in duodenal adenocarcinoma: a propensity score-adjusted analysis of Surveillance, Epidemiology, and End Results database.

Authors:  Yu Jin Lim; Kyubo Kim
Journal:  Int J Clin Oncol       Date:  2017-12-19       Impact factor: 3.402

Review 8.  Duodenal adenocarcinoma: Advances in diagnosis and surgical management.

Authors:  Jordan M Cloyd; Elizabeth George; Brendan C Visser
Journal:  World J Gastrointest Surg       Date:  2016-03-27

9.  A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis.

Authors:  Georgios Antonios Margonis; Mario Samaha; Yuhree Kim; Lauren McLendon Postlewait; Pamela Kunz; Shishir Maithel; Thuy Tran; Nickolas Berger; T Clark Gamblin; Matthew G Mullen; Todd W Bauer; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-03-23       Impact factor: 3.452

Review 10.  [Surgery for periampullary pancreatic cancer].

Authors:  Thomas Hank; Ulla Klaiber; Klaus Sahora; Martin Schindl; Oliver Strobel
Journal:  Chirurg       Date:  2021-07-14       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.